Abbott gains access to BG Medicine biomarker
Abbott and BG Medicine will partner to develop galectin-3, a protein that advances cardiac fibrosis, to better understand the evolution of heart failure.

The Abbott Park, Ill.-based company said the biomarker will be developed for its i1000SR and i2000SR Architect Immunochemistry instrument platforms.

Under the terms of agreement, Waltham, Mass.-based BG Medicine will grant rights to Abbott for its intellectual property of galectin-3. The companies have not yet released the financial ramifications of the agreement.